Replimune
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer.
REPL Key Statistics
Stock Snapshot
As of today, Replimune(REPL) shares are valued at $8.89. The company's market cap stands at 717.97M, with a P/E ratio of -2.43.
During the trading session on 2026-05-31, Replimune(REPL) shares reached a daily high of $9.49 and a low of $4.75. At a current price of $8.89, the stock is +87.1% higher than the low and still -6.3% under the high.
Trading volume for Replimune(REPL) stock has reached 51.37M, versus its average volume of 8.82M.
Over the past 52 weeks, Replimune(REPL) stock has traded between a high of $13.24 and a low of $1.50.
Over the past 52 weeks, Replimune(REPL) stock has traded between a high of $13.24 and a low of $1.50.
REPL News
Replimune (REPL) Group presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed me...
andrew kelly / Reuters The White House pushed health officials to re-examine the Food and Drug Administration’s repeated rejections of an advanced melanoma med...
As previously reported, JPMorgan analyst Anupam Rama upgraded Replimune (REPL) to Neutral from Underweight and established an $8 price target after the FDA and...
Analyst ratings
50%
of 8 ratingsMore REPL News
Shares of Replimune (REPL) are surging today after the biotech company announced that it plans to resubmit its melanoma drug RP1 for FDA approval after the trea...
Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...
U.S. stocks rose today, with the Dow Jones index rising around 171 points on Friday. The FDA had declined to approve vusolimogene oderparepvec, or RP1, in Apri...
Replimune plans to resubmit its melanoma drug to the Food and Drug Administration for review after a leadership exodus at the agency, the company said Friday....
FDA Commissioner Marty Makary Alex Wong / Getty Images Replimune REPL -0.43 %decrease; red down pointing triangle Group is expected to announce that it has rea...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.